Back to Search Start Over

Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.

Authors :
Rathbone E
Durant L
Kinsella J
Parker AR
Hassan-Smith G
Douglas MR
Curnow SJ
Source :
Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2018 Oct; Vol. 89 (10), pp. 1044-1049. Date of Electronic Publication: 2018 May 09.
Publication Year :
2018

Abstract

Objective: To determine whether the ratio of cerebrospinal fluid (CSF) immunoglobulin kappa to lambda light chains at time of multiple sclerosis (MS) diagnosis predicts disease progression and whether this was intrinsic to CSF plasmablasts.<br />Methods: CSF and peripheral blood were obtained from patients undergoing elective diagnostic lumbar puncture and included clinically isolated syndrome (CIS) (n=43), relapsing remitting MS (RRMS; n=50), primary progressive MS (PPMS; n=20) and other neurological disease controls, both inflammatory (ONID; n=23) and non-inflammatory (OND; n=114). CSF samples were assayed for free and immunoglobulin-associated light chains and on B cells and plasmablasts. Clinical follow-up data were collected during a 5-year follow-up period where available.<br />Results: There was an increased median CSF κ:λ free light chain (FLC) in all MS groups (CIS: 18.2, 95% CI 6.8 to 30.3; RRMS: 4.4, 95% CI 2.7 to 11.4; PPMS: 12.0, 95% CI 3.6 to 37.1) but not controls (OND: 1.61, 95% CI 1.4 to 1.9; ONID: 1.7, 95% CI 1.3 to 2.2; p<0.001). This ratio predicted Expanded Disability Status Scores (EDSS) progression at 5 years, with a lower median EDSS in the group with high (>10) CSF κ:λ FLC (0.0, 95% CI 0 to 2.5 vs 2.5, 95% CI 0 to 4, high vs low; p=0.049). CSF κ:λ FLC correlated with CSF IgG1 κ:λ (r=0.776; p<0.0001) and was intrinsic to CSF plasmablasts (r=0.65; p=0.026).<br />Conclusions: These data demonstrate that CSF immunoglobulin κ:λ ratios, determined at the time of diagnostic lumbar puncture, predict MS disease progression and may therefore be useful prognostic markers for early therapeutic stratification.<br />Competing Interests: Competing interests: ARP is an employee of The Binding Site Group Limited who manufacture the CSF FLC assays.<br /> (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)

Details

Language :
English
ISSN :
1468-330X
Volume :
89
Issue :
10
Database :
MEDLINE
Journal :
Journal of neurology, neurosurgery, and psychiatry
Publication Type :
Academic Journal
Accession number :
29743290
Full Text :
https://doi.org/10.1136/jnnp-2018-317947